References
1. Cresci S, Pereira NL, Ahmad F, Byku M, de Las Fuentes L, Lanfear DE,
et al. Heart Failure in the Era of Precision Medicine: A Scientific
Statement From the American Heart Association. Circ Genom Precis Med.
2019;12(10):458-85.
2. Hung CL, Chao TF, Su CH, Liao JN, Sung KT, Yeh HI, et al. Income
level and outcomes in patients with heart failure with universal health
coverage. Heart. 2020.
3. Clerkin KJ, Garan AR, Wayda B, Givens RC, Yuzefpolskaya M, Nakagawa
S, et al. Impact of Socioeconomic Status on Patients Supported With a
Left Ventricular Assist Device: An Analysis of the UNOS Database (United
Network for Organ Sharing). Circ Heart Fail. 2016;9(10).
4. Theochari CA, Michalopoulos G, Oikonomou EK, Giannopoulos S, Doulamis
IP, Villela MA, et al. Heart transplantation versus left ventricular
assist devices as destination therapy or bridge to transplantation for
1-year mortality: a systematic review and meta-analysis. Ann
Cardiothorac Surg. 2018;7(1):3-11.
5. Breathett K. Same Story, Different Disease: It Is Time to Change the
Storyline for Racial Minorities and Patients of Lower Socioeconomic
Status. Circ Heart Fail. 2018;11(3):e004931.
6. Hawkins NM, Jhund PS, McMurray JJ, Capewell S. Heart failure and
socioeconomic status: accumulating evidence of inequality. Eur J Heart
Fail. 2012;14(2):138-46.
7. Chair SY, Yu DS, Ng MT, Wang Q, Cheng HY, Wong EM, et al. Evolvement
of left ventricular assist device: the implications on heart failure
management. J Geriatr Cardiol. 2016;13(5):425-30.
8. Sanaiha Y, Downey P, Lyons R, Nsair A, Shemin RJ, Benharash P. Trends
in utilization, mortality, and resource use after implantation of left
ventricular assist devices in the United States. J Thorac Cardiovasc
Surg. 2020.
9. Tchoukina I, Shah KB, Thibodeau JT, Estep JD, Lala A, Lanfear DE, et
al. Impact of Socioeconomic Factors on Patient Desire for Early LVAD
Therapy Prior to Inotrope Dependence. J Card Fail. 2020;26(4):316-23.
10. Grady KL, Sherri W, Naftel DC, Myers S, Gelijins A, Moskowitz A, et
al. Age and gender differences and factors related to change in
health-related quality of life from before to 6 months after left
ventricular assist device implantation: Findings from Interagency
Registry for Mechanically Assisted Circulatory Support. J Heart Lung
Transplant. 2016;35(6):777-88.
11. Gupta RP, de Wit ML, McKeown D. The impact of poverty on the current
and future health status of children. Paediatr Child Health.
2007;12(8):667-72.
12. Schultz WM, Kelli HM, Lisko JC, Varghese T, Shen J, Sandesara P, et
al. Socioeconomic Status and Cardiovascular Outcomes: Challenges and
Interventions. Circulation. 2018;137(20):2166-78.
13. Carnethon MR, Pu J, Howard G, Albert MA, Anderson CAM, Bertoni AG,
et al. Cardiovascular Health in African Americans: A Scientific
Statement From the American Heart Association. Circulation.
2017;136(21):e393-e423.
14. Graham G. Disparities in cardiovascular disease risk in the United
States. Curr Cardiol Rev. 2015;11(3):238-45.
15. Flint KM, Matlock DD, Lindenfeld J, Allen LA. Frailty and the
selection of patients for destination therapy left ventricular assist
device. Circ Heart Fail. 2012;5(2):286-93.
16. Breathett K, Allen LA, Helmkamp L, Colborn K, Daugherty SL, Blair
IV, et al. Abstract 168: Racial and Ethnic Differences in Contemporary
Use of Left Ventricular Assist Device. Circulation: Cardiovascular
Quality and Outcomes. 2017;10(suppl_3):A168-A.
17. Lanfear AT, Hamandi M, Fan J, DiMaio JM, George TJ. Trends in
HeartMate 3: What we know so far. J Card Surg. 2020;35(1):180-7.
18. Ettner SL. New evidence on the relationship between income and
health. J Health Econ. 1996;15(1):67-85.
19. Hajat A, Kaufman JS, Rose KM, Siddiqi A, Thomas JC. Do the wealthy
have a health advantage? Cardiovascular disease risk factors and wealth.
Soc Sci Med. 2010;71(11):1935-42.
20. Ezzati M, Vander Hoorn S, Lawes CM, Leach R, James WP, Lopez AD, et
al. Rethinking the ”diseases of affluence” paradigm: global patterns of
nutritional risks in relation to economic development. PLoS Med.
2005;2(5):e133.
21. Bosch L, Assmann P, de Grauw WJC, Schalk BWM, Biermans MCJ. Heart
failure in primary care: prevalence related to age and comorbidity. Prim
Health Care Res Dev. 2019;20:e79.
22. Katherine Lietz JWL, Abdallah G. Kfoury, Mark S. Slaughter, Marc A.
Silver, Carmelo A. Milano, Joseph G. Rogers, Yoshifumi Naka, Donna
Mancini, and Leslie W. Miller. Outcomes of Left Ventricular Assist
Device Implantation as Destination Therapy in the Post-REMATCH Era.
Circulation. 2007;116:497-505.
23. Cerier E, Lampert BC, Kilic A, McDavid A, Deo SV, Kilic A. To
ventricular assist devices or not: When is implantation of a ventricular
assist device appropriate in advanced ambulatory heart failure? World J
Cardiol. 2016;8(12):695-702.
24. Baras Shreibati J, Goldhaber-Fiebert JD, Banerjee D, Owens DK,
Hlatky MA. Cost-Effectiveness of Left Ventricular Assist Devices in
Ambulatory Patients With Advanced Heart Failure. JACC Heart Fail.
2017;5(2):110-9.
25. Cotts WG, McGee EC, Jr., Myers SL, Naftel DC, Young JB, Kirklin JK,
et al. Predictors of hospital length of stay after implantation of a
left ventricular assist device: an analysis of the INTERMACS registry. J
Heart Lung Transplant. 2014;33(7):682-8.
26. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW,
Dembitsky W, et al. Long-term use of a left ventricular assist device
for end-stage heart failure. N Engl J Med. 2001;345(20):1435-43.
27. Marmot M. Social justice, epidemiology and health inequalities. Eur
J Epidemiol. 2017;32(7):537-46.
Table 1: Values are reported as mean ± standard deviation for continuous
variables. Categorical variables are represented as n (%).
Between-group comparisons were performed for continuous data using
T-test for parametric and Mann-Whitney U test for nonparametric
variables, respectively. Categorical variables were compared using Chi
squared test. p<0.001 considered for statistical significance
per Holm-Bonferroni correction for multiple comparisons. p value
considered significant <0.001 (bold). NS=Non-Significant.
Table 2: Values are reported as mean ± standard deviation and median
[IQR 25-75] for parametric and non-parametric continuous variables,
respectively. Categorical variables are represented as n (%).
Between-group comparisons were performed for continuous data using
T-test for parametric and Mann-Whitney U test for nonparametric
variables, respectively. Categorical variables were compared using Chi
squared test. p<0.001 considered for statistical significance
per Holm-Bonferroni correction for multiple comparisons. p value
considered significant <0.001 (bold). NS=Non-Significant.
Figure A: Number of left ventricular assist devices implanted per every
calendar year by income. Average increase per year of the low-income
group was 11% and for the high-income group was 8%.
Figure B: Median length of stay (LOS) in days in patients undergoing
left ventricular assist device (LVAD) implantation by income per every
calendar year. Variables were compared using Mann-Whitney U test with
p<0.001 considered for statistical significance (Black X).
Dots=Non-significant difference.
Figure C: Trend and comparison of inpatient all-cause mortality of
patients undergoing left ventricular assist device (LVAD) by income per
every calendar year. Variables were compared using Chi squared test with
p<0.001 considered for statistical significance (Black X).
Dots=Non-significant difference.